The figures I saw prior to release were that the split is 60:40 retail to hospital.
If that is correct, Fonda has about 26.4% market share overall (40% of 60% retail + 6% of 40% hospital), but with higher profitability in the retail segment.
As several others have pointed out, the gross/net distinction makes it difficult to work out what is going on. No choice but to just wait until we start seeing payments through to ACL.
My estimate is that at 40% of retail we will see about $US94m in gross sales, or around $US56m net if rebates etc. stay at current levels, with at least $15m in profit to ACL. This is easily enough to justify current price - the rest is just cream.
- Forums
- ASX - By Stock
- TSN
- article australian
article australian, page-17
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online